Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients

Michael E Stokes, Xin Ye, Manan Shah, Katie Mercaldi, Matthew W Reynolds, Marcia F T Rupnow, Jeffrey Hammond, Michael E Stokes, Xin Ye, Manan Shah, Katie Mercaldi, Matthew W Reynolds, Marcia F T Rupnow, Jeffrey Hammond

Abstract

Background: Inadequate surgical hemostasis may lead to transfusion and/or other bleeding-related complications. This study examines the incidence and costs of bleeding-related complications and/or blood product transfusions occurring as a consequence of surgery in various inpatient surgical cohorts.

Methods: A retrospective analysis was conducted using Premier's Perspective™ hospital database. Patients who had an inpatient procedure within a specialty of interest (cardiac, vascular, non-cardiac thoracic, solid organ, general, reproductive organ, knee/hip replacement, or spinal surgery) during 2006-2007 were identified. For each specialty, the rate of bleeding-related complications (including bleeding event, intervention to control for bleeding, and blood product transfusions) was examined, and hospital costs and length of stay (LOS) were compared between surgeries with and without bleeding-related complications. Incremental costs and ratios of average total hospital costs for patients with bleeding-related complications vs. those without complications were estimated using ordinary least squares (OLS) regression, adjusting for demographics, hospital characteristics, and other baseline characteristics. Models using generalized estimating equations (GEE) were also used to measure the impact of bleeding-related complications on costs while accounting for the effects related to the clustering of patients receiving care from the same hospitals.

Results: A total of 103,829 cardiac, 216,199 vascular, 142,562 non-cardiac thoracic, 45,687 solid organ, 362,512 general, 384,132 reproductive organ, 246,815 knee/hip replacement, and 107,187 spinal surgeries were identified. Overall, the rate of bleeding-related complications was 29.9% and ranged from 7.5% to 47.4% for reproductive organ and cardiac, respectively. Overall, incremental LOS associated with bleeding-related complications or transfusions (unadjusted for covariates) was 6.0 days and ranged from 1.3 to 9.6 days for knee/hip replacement and non-cardiac thoracic, respectively. The incremental cost per hospitalization associated with bleeding-related complications and adjusted for covariates was highest for spinal surgery ($17,279) followed by vascular ($15,123), solid organ ($13,210), non-cardiac thoracic ($13,473), cardiac ($10,279), general ($4,354), knee/hip replacement ($3,005), and reproductive organ ($2,805).

Conclusions: This study characterizes the increased hospital LOS and cost associated with bleeding-related complications and/or transfusions occurring as a consequence of surgery, and supports implementation of blood-conservation strategies.

Figures

Figure 1
Figure 1
Mean Hospital LOS and ICU Days by Surgical Cohort and Complication Status.
Figure 2
Figure 2
Mean Total Adjusted1 Hospital Costs (95% CIs) in 2007 $US by Surgical Cohort.

References

    1. Shander A. Financial and clinical outcomes associated with surgical bleeding complications. Surgery. 2007;142(4 Suppl):S20–25.
    1. Rady MY, Ryan T, Starr NJ. Perioperative determinants of morbidity and mortality in elderly patients undergoing cardiac surgery. Crit Care Med. 1998;26(2):225–235. doi: 10.1097/00003246-199802000-00016.
    1. Marietta M, Facchini L, Pedrazzi P, Busani S, Torelli G. Pathophysiology of bleeding in surgery. Transplant Proc. 2006;38(3):812–814. doi: 10.1016/j.transproceed.2006.01.047.
    1. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E. et al.Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11(1):R17. doi: 10.1186/cc5686.
    1. Maluenda G, Lemesle G, Ben-Dor I, Collins SD, Syed AI, Li Y, Torguson R, Kaneshige K, Xue Z, Suddath WO. et al.Value of blood transfusion in patients with a blood hematocrit of 24% to 30% after percutaneous coronary intervention. Am J Cardiol. 2009;104(8):1069–1073. doi: 10.1016/j.amjcard.2009.06.006.
    1. O'Neill WW. Risk of bleeding after elective percutaneous coronary intervention. N Engl J Med. 2006;355(10):1058–1060. doi: 10.1056/NEJMe068133.
    1. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF. et al.Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930–935. doi: 10.1016/S0002-9149(03)00972-X.
    1. Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K, Cappadoro C, Fu M, Plisco MS. et al.Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med. 2006;34(9):2302–2308. doi: 10.1097/01.CCM.0000234034.51040.7F. quiz 2309.
    1. Rogers MA, Blumberg N, Saint S, Langa KM, Nallamothu BK. Hospital variation in transfusion and infection after cardiac surgery: a cohort study. BMC Med. 2009;7:37. doi: 10.1186/1741-7015-7-37.
    1. Spiess BD. Blood transfusion: the silent epidemic. Ann Thorac Surg. 2001;72(5):S1832–1837. doi: 10.1016/S0003-4975(01)03259-3.
    1. Toy P, Lowell C. TRALI--definition, mechanisms, incidence and clinical relevance. Best Pract Res Clin Anaesthesiol. 2007;21(2):183–193. doi: 10.1016/j.bpa.2007.01.003.
    1. Robb WJ. Massive transfusion in trauma. AACN Clin Issues. 1999;10(1):69–84. doi: 10.1097/00044067-199902000-00007. quiz 138-140.
    1. Engoren M, Mitchell E, Perring P, Sferra J. The effect of erythrocyte blood transfusions on survival after surgery for hip fracture. J Trauma. 2008;65(6):1411–1415. doi: 10.1097/TA.0b013e318157d9f9.
    1. DeFrances C, Lucas C, Buie V, Golosinskiy A. National Health Statistics Reports. Vol. 5. Hyattsville, MD: National Center for Health Statistics; 2008. 2006 National Hospital Discharge Survey.
    1. Premier Inc. Premier Perspective™. Charlotte, NC: Premier Inc; 2009.
    1. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Comparative Effectiveness Review No 21. Rockville, MD: Agency for Healthcare Research and Quality; 2010. Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care. #290-02-0017 S-UE-bPCuCN.
    1. Facts and Figures 2007 - Table of Contents. Healthcare Cost and Utilization Project (HCUP) September 2009.
    1. Regulations and Ethical Guidelines: Title 45 Public Welfare Department of Health and Human Services, Part 46 Protection of Human Subjects. Revised June 23, 2005.
    1. Blanchette CM, Wang PF, Joshi AV, Asmussen M, Saunders W, Kruse P. Cost and utilization of blood transfusion associated with spinal surgeries in the United States. Eur Spine J. 2007;16(3):353–363. doi: 10.1007/s00586-006-0066-3.
    1. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc. 1983;78(383):605–610. doi: 10.2307/2288126.
    1. Hemmila MR, Jakubus JL, Maggio PM, Wahl WL, Dimick JB, Campbell DA Jr, Taheri PA. Real money: complications and hospital costs in trauma patients. Surgery. 2008;144(2):307–316. doi: 10.1016/j.surg.2008.05.003.
    1. Jacobson KM, Hall Long K, McMurtry EK, Naessens JM, Rihal CS. The economic burden of complications during percutaneous coronary intervention. Qual Saf Health Care. 2007;16(2):154–159. doi: 10.1136/qshc.2006.019331.
    1. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res. 2006;117(5):569–577. doi: 10.1016/j.thromres.2005.04.018.
    1. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2010.
    1. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17(3):283–295. doi: 10.1016/S0167-6296(98)00025-3.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi